Park Hee Sue, Choi Jungeun, See Cha Ja, Kim Jung Ah, Park Si Nae, Im Kyongok, Kim Sung Min, Lee Dong Soon, Hwang Sang Mee
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea.
Department of Laboratory Medicine, Korea University Anam Hospital, Seoul, Korea.
Ann Lab Med. 2017 May;37(3):195-203. doi: 10.3343/alm.2017.37.3.195.
Telomere shortening is thought to be involved in the pathophysiology of myeloid malignancies, but telomere lengths (TL) during interphase and metaphase in hematopoietic malignancies have not been analyzed. We aimed to assess the TLs of interphase and metaphase cells of MDS and telomerase activity (TA) and to find out prognostic significances of TL and TA.
The prognostic significance of TA by quantitative PCR and TL by quantitative fluorescence in situ hybridization (QFISH) of interphase nuclei and metaphase chromosome arms of bone marrow cells from patients with MDS were evaluated.
MDS patients had shorter interphase TL than normal healthy donors (P<0.001). Average interphase and metaphase TL were inversely correlated (P=0.013, p arm; P=0.029, q arm), but there was no statistically significant correlation between TA and TL (P=0.258). The progression free survival was significantly shorter in patients with high TA, but the overall survival was not different according to average TA or interphase TL groups. Multivariable Cox analysis showed that old age, higher International Prognostic Scoring System (IPSS) subtypes, transformation to AML, no history of hematopoietic stem cell transplantation and short average interphase TL (<433 TL) as independent prognostic factors for poorer survival (P=0.003, 0.001, 0.005, 0.005, and 0.013, respectively).
The lack of correlation between age and TL, TA, and TL, and the inverse relationship between TL and TA in MDS patients reflect the dysregulation of telomere status and proliferation. As a prognostic marker for leukemia progression, TA may be considered, and since interphase TL has the advantage of automated measurement by QFISH, it may be used as a prognostic marker for survival in MDS.
端粒缩短被认为与髓系恶性肿瘤的病理生理学有关,但尚未分析造血恶性肿瘤间期和中期的端粒长度(TL)。我们旨在评估骨髓增生异常综合征(MDS)间期和中期细胞的端粒长度以及端粒酶活性(TA),并找出端粒长度和端粒酶活性的预后意义。
通过定量聚合酶链反应评估TA的预后意义,通过定量荧光原位杂交(QFISH)评估MDS患者骨髓细胞间期核和中期染色体臂的TL。
MDS患者的间期TL比正常健康供体短(P<0.001)。平均间期和中期TL呈负相关(P=0.013,p臂;P=0.029,q臂),但TA与TL之间无统计学显著相关性(P=0.258)。TA高的患者无进展生存期明显较短,但根据平均TA或间期TL分组,总生存期无差异。多变量Cox分析显示,高龄、较高的国际预后评分系统(IPSS)亚型、转化为急性髓系白血病(AML)、无造血干细胞移植史以及平均间期TL短(<433个端粒)是生存较差的独立预后因素(分别为P=0.003、0.001、0.005、0.005和0.013)。
MDS患者年龄与TL、TA和TL之间缺乏相关性,以及TL与TA之间的负相关关系反映了端粒状态和增殖的失调。作为白血病进展的预后标志物,可考虑TA,由于间期TL具有通过QFISH自动测量的优势,它可作为MDS生存的预后标志物。